NSCLC cell lines with mutant KRAS exhibited significantly lower survival rates upon treatment with the CERK inhibitor NVP-231 compared to those with wild-type KRAS, indicating a specific vulnerability of KRAS-mutated cells to CERK inhibition. This evidence concerns the gene KRAS and non-small cell lung carcinoma.